Abstract:
Alzheimer’s disease (AD) is the most common cause of dementia and cognitive impairment; yet, there is currently no treatment.
A buildup of Aβ, tau protein phosphorylation, oxidative stress, and inflammation in AD is pathogenic. The accumulation
of amyloid-beta (Aβ) peptides in these neurocognitive areas is a significant characteristic of the disease. Therefore,
inhibiting Aβ peptide aggregation has been proposed as the critical therapeutic approach for AD treatment. Resveratrol has
been demonstrated in multiple studies to have a neuroprotective, anti-inflammatory, and antioxidant characteristic and the
ability to minimize Aβ peptides aggregation and toxicity in the hippocampus of Alzheimer’s patients, stimulating neurogenesis
and inhibiting hippocampal degeneration. Furthermore, resveratrol’s antioxidant effect promotes neuronal development
by activating the silent information regulator-1 (SIRT1), which can protect against the detrimental effects of oxidative stress.
Resveratrol-induced SIRT1 activation is becoming more crucial in developing novel therapeutic options for AD and other
diseases that have neurodegenerative characteristics. This review highlighted a better knowledge of resveratrol’s mechanism
of action and its promising therapeutic efficacy in treating AD. We also highlighted
